# Cardio Diagnostics Holdings, Inc.: overview

CDIO · Nasdaq · CIK 1870144 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cdio.md) · [Financials](/companies/cdio/financials.md) · [Filings](/companies/cdio/filings.md) · [Insiders](/companies/cdio/insiders.md)

Latest reported revenue: [$5.4k](/filings/0001079973-26-001016.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:Revenues, accession 0001079973-26-001016).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [6.6](/filings/0001079973-25-001686.md) | [4.5 d](/filings/0001553350-26-000023.md) | [0.9](/filings/0001553350-26-000089.md) | [7.5](/filings/0001079973-26-001016.md) | [2.9](/filings/0001079973-25-001686.md) | [3.6 d](/filings/0001553350-26-000023.md) | [2.7](/filings/0001553350-26-000089.md) | [5.4](/filings/0001079973-26-001016.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(21412.9%)](/filings/0001079973-25-001686.md) | [(33608.2%) d](/filings/0001553350-26-000023.md) | [(173463.8%)](/filings/0001553350-26-000089.md) | [(22457.5%)](/filings/0001079973-26-001016.md) | [(59950.9%)](/filings/0001079973-25-001686.md) | [(41159.5%) d](/filings/0001553350-26-000023.md) | [(66598.4%)](/filings/0001553350-26-000089.md) | [(27950.5%)](/filings/0001079973-26-001016.md) |
| Net margin | % | [(21467.6%)](/filings/0001079973-25-001686.md) | [(33672.6%) d](/filings/0001553350-26-000023.md) | [(173943.0%)](/filings/0001553350-26-000089.md) | [(22517.7%)](/filings/0001079973-26-001016.md) | [(60053.8%)](/filings/0001079973-25-001686.md) | [(41219.9%) d](/filings/0001553350-26-000023.md) | [(66722.3%)](/filings/0001553350-26-000089.md) | [(28012.5%)](/filings/0001079973-26-001016.md) |
| Diluted EPS | $ per share | [(1.73)](/filings/0001079973-25-001686.md) | not reported | [(0.97)](/filings/0001553350-26-000089.md) | [(0.97)](/filings/0001079973-26-001016.md) | [(0.98)](/filings/0001079973-25-001686.md) | not reported | [(0.63)](/filings/0001553350-26-000089.md) | [(0.51)](/filings/0001079973-26-001016.md) |
| Free cash flow | $k | [(1,181) d](/filings/0001079973-25-001686.md) | [(1,396) d](/filings/0001553350-26-000023.md) | [(1,406)](/filings/0001553350-26-000089.md) | [(1,590) d](/filings/0001079973-26-001016.md) | [(1,556) d](/filings/0001079973-25-001686.md) | [(1,362) d](/filings/0001553350-26-000023.md) | [(1,564)](/filings/0001553350-26-000089.md) | [(1,342) d](/filings/0001079973-26-001016.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.9](/filings/0001079973-23-000412.md) | [1.0](/filings/0001079973-24-000480.md) | [17.1](/filings/0001079973-25-000428.md) | [34.9](/filings/0001553350-26-000023.md) | [14.8](/filings/0001553350-26-000023.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(68862.2%)](/filings/0001079973-23-000412.md) | [(478784.3%)](/filings/0001079973-24-000480.md) | [(42440.4%)](/filings/0001079973-25-000428.md) | [(23977.9%)](/filings/0001553350-26-000023.md) | [(43737.5%)](/filings/0001553350-26-000023.md) |
| Net margin | % | [(68862.2%)](/filings/0001079973-23-000412.md) | [(490630.0%)](/filings/0001079973-24-000480.md) | [(49087.8%)](/filings/0001079973-25-000428.md) | [(24028.2%)](/filings/0001553350-26-000023.md) | [(43832.5%)](/filings/0001553350-26-000023.md) |
| Diluted EPS | $ per share | [(0.53)](/filings/0001079973-23-000412.md) | [(1.51)](/filings/0001079973-24-000480.md) | [(0.66)](/filings/0001079973-25-000428.md) | [(9.35)](/filings/0001553350-26-000023.md) | [(3.71)](/filings/0001553350-26-000023.md) |
| Free cash flow | $k | not reported | not reported | [(6,248)](/filings/0001079973-25-000428.md) | [(5,208)](/filings/0001553350-26-000023.md) | [(5,914)](/filings/0001553350-26-000023.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cdio/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $132.6k | 60,540 |  | Unchanged |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $107.7k | 49,200 |  | Added +33,852 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $76.0k | 34,708 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $57.4k | 26,233 |  | Reduced −5,944 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $44.1k | 20,155 |  | Unchanged |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $41.8k | 19,071 |  | New +19,071 |
| [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $35.2k | 16,093 |  | New +16,093 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $26.1k | 11,933 |  | Reduced −69,350 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $22.1k | 10,099 |  | New +10,099 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $6.2k | 2,824 |  | Reduced −1,145 |

## Recent filings

[All 295 filings](/companies/cdio/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-18 | 20:45 ET | [8-K](/filings/0001553350-26-000131.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001553350-26-000131 |
| 2026-08-20 | 12:03 ET | [8-K](/filings/0001079973-26-001153.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001079973-26-001153 |
| 2026-08-07 | 20:30 ET | [10-Q](/filings/0001079973-26-001016.md) | Quarterly report, period 2026-06-30 | 0001079973-26-001016 |
| 2026-08-05 | 20:30 ET | [DEF 14A](/filings/0001079973-26-001003.md) | Proxy statement, period 2026-09-18 | 0001079973-26-001003 |
| 2026-05-15 | 20:35 ET | [10-Q](/filings/0001553350-26-000089.md) | Quarterly report, period 2026-03-31 | 0001553350-26-000089 |
| 2026-03-13 | 21:18 ET | [10-K](/filings/0001553350-26-000023.md) | Annual report, period 2025-12-31 | 0001553350-26-000023 |
| 2026-02-19 | 13:00 ET | [8-K](/filings/0001079973-26-000239.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001079973-26-000239 |
| 2025-11-12 | 21:30 ET | [10-Q](/filings/0001079973-25-001686.md) | Quarterly report, period 2025-09-30 | 0001079973-25-001686 |
| 2025-10-15 | 20:45 ET | [8-K](/filings/0001079973-25-001612.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001079973-25-001612 |
| 2025-09-04 | 12:00 ET | [DEF 14A](/filings/0001079973-25-001419.md) | Proxy statement, period 2025-10-15 | 0001079973-25-001419 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001553350-26-000023.md), filed Mar 13, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/54b1e43d-ca1e-415b-884a-0ce268997ea2)

## About the filer

- CIK: 1870144
- Tickers: CDIO, CDIOW
- Exchange: Nasdaq
- SIC code: 2835 In Vitro & In Vivo Diagnostic Substances
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.